Flex Pharma is a biotechnology company that is developing treatments for muscle cramps and spasms associated with severe neurological conditions and exercise-associated muscle cramps. The Company's lead drug product candidate, FLX-787, is currently in exploratory Phase 2 clinical trials in Australia in patients with multiple sclerosis, or MS, and amyotrophic lateral sclerosis, or ALS.It expect to initiate a Phase 2 clinical trial in the United States of FLX-787 in patients with motor neuron disease, primarily with ALS, and another Phase 2 clinical trial in patients with Charcot-Marie-Tooth disease, or CMT. In addition, Flex Pharma launched its consumer product, HOTSHOT, to prevent and treat exercise-associated muscle cramps, or EAMCs.
|USD||Q1, 2015||Q2, 2015||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017||Q1, 2018|
|110.5 m||106 m||89.2 m||54 m||38.9 m||27.8 m||21.1 m||39.1 m||21.9 m|
|11.6 k||21.8 k||19.1 k||34.7 k||12.6 k|
|112.6 k||274.3 k||230.8 k||414.3 k||688.2 k||418.2 k|
|111.6 m||106.8 m||100.2 m||86.5 m||77.4 m||69.1 m||54.8 m||49.1 m||25.6 m|
Flex Pharma revenue breakdown by business segment: 100.0% from Consumer Operations and 0.0% from Other